Skip to content

Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study

Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018572
Enrollment
Unknown
Registered
2018-09-25
Start date
2017-01-01
Completion date
Unknown
Last updated
2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Group 2:progesterone+dydrogesterone
Group 1:progesterone+dydrogesterone + GnRHa 0.1mg

Sponsors

First Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: (1) Aged < 40 years old; (2) Basic FSH < 12 mIu / ml; (3) At least one transplanted embryo; (4) Controlled hyperstimulation with GnRH antagonist regimen; (5) Routine IVF or ICSI; (6) Serum progesterone < 3.0 ng / ml on HCG day of ovulation induction; and (7) ART treatment for the first time.

Exclusion criteria

Exclusion criteria: (1) On the day of HCG, the serum progesterone level of the patients was higher than 3.0 ng/ml; (2) the patients had moderate or severe hydrosalpinx; (3) on the day of transplantation, B-mode ultrasonography suggested hydrosalpinx reflux (uterine separation); and (4) on the day of transplantation, B-mode ultrasonography showed that the endometrium of the patients was less than 7 mm or the thickness of endometrium was more than 15 mm; (5) submucous myoma and congenital uterine malformation. (biangular uterus, uniangular uterus, complete or incomplete uterine diaphragm), intrauterine adhesion; _3 days after oocyte retrieval, the patient cancelled the transplantation or changed to the 5th day of transplantation; _OHSS high risk (the number of bilateral ovarian follicles on the day of HCG < 20, E2 < 5000pg / ml); poor compliance.

Design outcomes

Primary

MeasureTime frame
live birth rate;Clinical pregnancy rate;Continuous pregnancy rate;Early abortion rate;Ectopic pregnancy rate;Multiple pregnancy rate;Embryo implantation rate;Incidence of OHSS;

Countries

China

Contacts

Public ContactMa Xiaoling

First Hospital of Lanzhou University

maxl2015@163.com+86 13893690488

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026